Xiaochuan Yang

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

B. Smith, P. White, M. Levis, 2011, Blood.

Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features

M. Geyer, Xiaochuan Yang, Filiz Şen, 2019, Leukemia research reports.

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.

G. Nybakken, M. Borowitz, B. Smith, 2012, Blood.

Further Activation of FLT3 Mutants by FLT3 Ligand

M. Levis, D. Small, Xiaochuan Yang, 2011, Oncogene.

Bone marrow stroma‐mediated resistance to FLT3 inhibitors in FLT3‐ITD AML is mediated by persistent activation of extracellular regulated kinase

M. Levis, Xiaochuan Yang, Amy N. Sexauer, 2014, British journal of haematology.

Runx1 Regulates Myeloid Precursor Differentiation Into Osteoclasts Without Affecting Differentiation Into Antigen Presenting or Phagocytic Cells in Both Males and Females.

H. Drissi, Xiaochuan Yang, J. Kalinowski, 2016, Endocrinology.

Tumor Growth Assessment by Computed Tomography Perfusion Imaging (CTPI), Perfusion-Weighted Imaging (PWI), and Diffusion-Weighted Imaging (DWI) in a Rabbit Pleural Squamous Cell Carcinoma VX2-Implanted Model

Qiang Zhang, Xiaochuan Yang, C. Ba, 2018, Medical science monitor : international medical journal of experimental and clinical research.

Persistent ERK Activation in Bone Marrow Blasts May Account for the Difference in Bone Marrow Versus Peripheral Blood Response to FLT3 Inhibition in FLT3/ITD AML

M. Levis, Xiaochuan Yang, Amy N Sexauer, 2011 .

Runx1 Regulates Myeloid Precursor Differentiation Into Osteoclasts Without Affecting Differentiation Into Antigen Presenting or Phagocytic Cells in Both Males and Females.

H. Drissi, Xiaochuan Yang, J. Kalinowski, 2016, Endocrinology.